

## REMARKS

Claims 1-28 are presently pending in the application.

The Examiner has required restriction under 35 U.S.C. § 121 to one of the following groups:

Group I. Claims 1-19 in part, drawn to a method of treating or preventing a disease resulting from a somatic mutation involving a compound of formula I in which X represents oxygen or sulfur;

Group II. Claims 1-19 in part, drawn to a method of treating or preventing a disease resulting from a somatic mutation involving a compound of formula I in which X represents NH;

Group III. Claims 1-19 in part, drawn to a method of treating or preventing a disease resulting from a somatic mutation involving a compound of formula I in which X represents CH<sub>2</sub>;

Group IV. Claims 20-25 in part, drawn to a compound having a structure described by formula II, in which X represents oxygen or sulfur, and both A and B represent carbon;

Group V. Claims 20-25 in part, drawn to a compound having a structure described by formula II, in which X represents NH, and both A and B represent carbon;

Group VI. Claims 20-25 in part, drawn to a compound having a structure described by formula II, in which X represents CH<sub>2</sub>, and both A and B represent carbon;

Group VII. Claims 20-25 and 28, in part, drawn to a compound having a structure described by formula II, in which X represents oxygen or sulfur, and exactly one of A or B represents nitrogen;

Group VIII. Claims 20-25 and 28, in part, drawn to a compound having a structure described by formula II, in which X represents NH, and exactly one of A or B represents nitrogen;

Group IX. Claims 20-25 and 28, in part, drawn to a compound having a structure described by formula II, in which X represents CH<sub>2</sub>, and exactly one of A or B represents nitrogen;


Group X. Claims 20-28 in part, drawn to a compound having a structure described by formula II, in which X represents sulfur or oxygen, and A and B both represent nitrogen;

Group XI. Claims 20-26 and 28, in part, drawn to a compound having a structure described by formula II, in which X represents NH, and A and B both represent nitrogen; and

Group XII. Claims 20-26 and 28, in part, drawn to a compound having a structure described by formula II, in which X represents CH<sub>2</sub>, and A and B both represent nitrogen.

In response, Applicant elects Group I, Claims 1-19 in part, drawn to a method of treating or preventing a disease resulting from a somatic mutation involving a compound of formula I in which X represents oxygen or sulfur.

In addition, the further election of a compound species is required. In response, Applicant elects without traverse 6-amino-5-nitro-4-( $\beta$ -D-ribofuranosylamino)pyrimidine, which has the following structure:



In addition, the further election of a disease species is required. In response, Applicant elects without traverse cancer.

Pending claims 1-19 read on the elected species.

Applicant respectfully requests that the above remarks be entered in the present application file. No fee is believed to be due in connection with this Response as it is being timely filed within one month of the mailing date of the Office action (May 14, 2006 being a Sunday); however, in the event that any fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*

*By: Michael J. Bruner, Reg. No. 47,458*

Date May 15, 2006

By: Michael J. Bruner (Reg. No. 47,458)

**JONES DAY**

222 East 41st Street  
New York, New York 10017  
(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**

12750 High Bluff Drive, Suite 300  
San Diego, California 92130  
(858) 314-1130